About this Research Topic
Cancer therapy has rapidly expanded and advanced in recent years. Consequently, cancer therapy-related adverse events and toxicities have been increasingly recognized across different organ systems. There is an urgent need to expand our knowledge and raise awareness of these toxicities to improve cancer care and patient outcomes. Fostering research in this field is a crucial starting point to achieve this goal.
In this Research Topic, we will gather a diverse collection of scientific articles focusing on the mechanistic investigation on various organ toxicities related to cancer therapy. Centralizing these publications will provide a valuable reference for readers interested in this topic, allowing them to gain comprehensive knowledge, apply it in their clinical practice, and foster future research.
We welcome original research articles, reviews, and case series. The scope of the Research Topic encompasses, but is not limited to, the following themes:
• Different cancer therapies, including but not limited to immune checkpoint inhibitors, CAR T, TKI, targeted therapy, radiation, etc.
• Different organ toxicities, including but not limited to skin, GI, liver, kidney etc.
• Unique translational investigation on the mechanism of action and correlation between clinical and immunological presentations.
Please note that Dr. Yinghong Wang is a consultant with AzurRx, BionTech/OncoC4, Ilyapharma, IOTA, Janssen, Kanvas Bio, MabQuest, Mallinckrodt, -Sanarentero, Sorriso, Gilead, Alimentiv. Further, Dr Wang has received research grant from Gateway, Adopt A Scientist, Moonshot, HESI, Sabin Fellowship, 3D-matrix, Janssen.
Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
In this Research Topic, we will gather a diverse collection of scientific articles focusing on the mechanistic investigation on various organ toxicities related to cancer therapy. Centralizing these publications will provide a valuable reference for readers interested in this topic, allowing them to gain comprehensive knowledge, apply it in their clinical practice, and foster future research.
We welcome original research articles, reviews, and case series. The scope of the Research Topic encompasses, but is not limited to, the following themes:
• Different cancer therapies, including but not limited to immune checkpoint inhibitors, CAR T, TKI, targeted therapy, radiation, etc.
• Different organ toxicities, including but not limited to skin, GI, liver, kidney etc.
• Unique translational investigation on the mechanism of action and correlation between clinical and immunological presentations.
Please note that Dr. Yinghong Wang is a consultant with AzurRx, BionTech/OncoC4, Ilyapharma, IOTA, Janssen, Kanvas Bio, MabQuest, Mallinckrodt, -Sanarentero, Sorriso, Gilead, Alimentiv. Further, Dr Wang has received research grant from Gateway, Adopt A Scientist, Moonshot, HESI, Sabin Fellowship, 3D-matrix, Janssen.
Please also note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords: Cancer therapy, immunotherapy, immune checkpoint inhibitors, toxicities, adverse events
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
